Is cyclosporine in renal-transplant recipients more effective when given twice a day than in a single daily dose?

Transplantation

Volumn 78, Issue 5, 2004, Pages 675-680

  Tarantino, Antonio ^a   Passerini, Patrizia ^a   Campise, Mariarosaria ^a   Bonizzoni, Erminio ^b   Ceccarini, Fulvia ^a   Montagnino, Giuseppe ^a   Aroldi, Adriana ^a   Ponticelli, Claudio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; UREA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT REJECTION; HEART INFARCTION; HERPES VIRUS INFECTION; HIRSUTISM; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PARESTHESIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TENDINITIS; THROMBOSIS; TREMOR;

ADULT; AREA UNDER CURVE; CREATININE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; EMULSIONS; FEMALE; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 4544299957     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000129806.69681.15     Document Type: Article

References (32)

1. Kahan BD. Overview: individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985; 40: 457.
2. Lindholm A, Welsh M, Rutzky L, et al. The adverse impact of high cyclosporine clearance rates on the incidence of acute rejection and graft loss. Transplantation 1993; 55: 985.
3. Meyer MM, Munar M, Udeaja J, et al. Efficacy of area under the curve monitoring in renal transplantation. J Am Soc Nephrol 1993; 4: 1306.
4. Citterio F, Scatà MC, Borzi MT, et al. C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplantation recipients. Transplant Proc 2001; 33: 3133.
5. Ponticelli C, Yussim A, Cambi V. A randomized double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001; 72: 1261.
6. Nievergelt Y. UMAP: Module 718. Splines in single and multivariable calculus. Lexington, MA, COMAP 1993.
7. Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Clin Transplant 1996; 62: 599.
8. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55(2): 713.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
10. Ponticelli C, Villa M, Cesana B, et al. Risk factors for late kidney allograft failure. Kidney Int 2002; 62: 1848.
11. Montagnino G, Tarantino A, Maccario M, et al. Long-term results with cyclosporine monotherapy in renal transplant patients: a multivariate analysis of risk factors. Am J Kidney Dis 2000; 35: 1135.
12. Bennet MW, Lindsly J, Buss CW. The effects of age and dosage route on experimental cyclosporine nephrotoxicity. Transplantation 1991; 51: 730.
13. Frey FJ. Pharmacokinetic determinants of cyclosporin and prednisone in renal transplant patients. Kidney Int 1991; 39: 1034.
14. Grevel J, Kahan BD. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem 1991; 37: 1905.
15. Chishti AS, Sorof JM, Brewer ED, et al. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis 2001; 38: 754.
16. Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2: 789.
17. Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression to cyclosporin AUC 0-12 monitoring in cardiac transplant recipients over the first year post-transplantation. Eur J Clin Pharmacol 2003; 58: 813.
18. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 1999; 68: 55.
19. Perner F for the International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148.
20. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658.
21. Rosso Felipe C, Tedesco Silva H Jr, Goulart Pinheiro Machado P, et al. Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. Transpl Int 2003; 16: 494.
22. Schädeli F, Marti H-P, Frey FJ, et al. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients. Clin Pharmacokinet 2002; 41: 59.
23. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356.
24. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem 1999; 45: 1477.
25. Caruso R, Perico N, Cattaneo D, et al. In renal transplant recipients whole blood calcineurin activity is not predicted by cyclosporine blood levels. Clin Chem 2001; 47: 1679.
26. 2 monitoring: a review. Transplantation 2002; 73: S3.
27. Campbell SB, Johnson DW. Patient management by cyclosporine C2 monitoring: not enough science yet to justify the practice. Transplantation 2003; 75: 1917.
28. Grant D, Kneteman N, Tchervenkov J, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection. Transplantation 1999; 67: 1133.
29. Clase CM, Mahalati K, Kiberd BA, et al. A comparison of the ability of different markers of cyclosporine exposure to predict acute rejection in renal transplant recipients. Am J Transplant 2001; 1(suppl): 383.
30. Vathsala A, Lu YM. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice. Transplant Proc 2001; 33: 3137.
31. 2- cyclosporine levels and time to initiation of cyclosporine therapy on outcomes in patients receiving Neoral and Simulect. J Am Soc Nephrol 2000; 11: 703A.
32. 2). Transplantation 2002; 73: 953.